How this pharma company is thriving despite industry headwinds

Published: 07th Aug 2024 By: Value Research

A mighty small cap

[{"selector":"#anim-6aaa3892-ddfb-4398-9982-e9cc40d22bfb","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6ffa10cd-2ad5-4e3b-9d21-6eaab62aabbe","keyframes":{"transform":["translate3d(0px, 153.47870%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Major pharma API manufacturers have seen their growth moderate after the Covid peak, except for Neuland Laboratories that has been resilient against industry downturns.

Exemplary gains

[{"selector":"#anim-284d3164-f7da-43bf-b91d-ad0e8f60e29c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f60c28f3-66d8-4132-9918-bbfaeb7b0c8a","keyframes":{"transform":["translate3d(0px, 153.47870%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Since FY21, its annual revenue & operating profit have grown remarkably by 18% and 55% , respectively, against sluggish industry growth. Its stock, too, skyrocketed 2.5x in the last year!

Thank the game changing pivot in FY21

[{"selector":"#anim-16902156-028a-4642-9deb-3757250bf838","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-02884e5a-c5ed-46f5-a43f-b3f79655459c","keyframes":{"transform":["translate3d(0px, 126.32480%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] While generic API makers were pressured due to price erosion & demand slowdown post Covid, Neuland’s solid growth came from its pivot to custom manufacturing services (CMS) .

[{"selector":"#anim-4d66a8d3-7e5f-4d26-b1ff-ab03e1d73f57","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e4e8eb63-2536-4079-979e-f2b76d782756","keyframes":{"transform":["translate3d(0px, 153.47870%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Under CMS, it is producing high-margin complex APIs uniquely tailored for each client. This has boosted its operating profit margins from 10% in FY20 to 26% in FY24!

What’s in store ahead for Neuland?

[{"selector":"#anim-177132e8-10bd-4338-8c0d-38890604ff47","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-54e84732-0034-4c16-abb6-a89138cd31c7","keyframes":{"transform":["translate3d(0px, 153.47870%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] It is among the fastest-growing Indian pharma companies, but can its growth hold up? What are the risks that plague its prospects? Head to our story & find out. Click the link below. How this small-cap pharma company is defying industry odds

Other Webstories

[{"selector":"#anim-749e9c84-06b5-4155-a304-d9ed6350fe44","keyframes":{"opacity":[0,1]},"delay":200,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e7e2a9ac-1c32-4751-b997-49780dc69a13","keyframes":{"transform":["translate3d(-125.51724%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":200,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-8afce3c1-ef47-49c5-8161-f8240f9613ff","keyframes":{"opacity":[0,1]},"delay":300,"duration":2000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f893ed9d-c840-4f5d-b73d-b9b1e963120d","keyframes":{"opacity":[0,1]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-16de19df-fd0d-4e5b-917f-d423ed6390c6","keyframes":{"transform":["translate3d(-194.52735%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":400,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-815f2401-4614-408c-aadb-ee9e7eed2f60","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-95959e5f-41d9-4e46-a1a5-964bdf55090d","keyframes":{"transform":["translate3d(-125.51724%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Click Here

How this pharma company is thriving despite industry headwinds

A mighty small cap

Exemplary gains

Thank the game changing pivot in FY21

You May Also Like

Solid push to profitability

What’s in store ahead for Neuland?

Other Webstories

Unicommerce eSolutions IPO: The good and the bad

Watch Next WebStory